Development
Takeda Pharmaceutical Company Limited
TAK
$15.30
-$0.22-1.42%
NYSE
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 1.27B | 1.40B | 2.18B | 2.34B | 2.00B |
| Total Depreciation and Amortization | 4.81B | 4.80B | 4.75B | 4.72B | 4.76B |
| Total Amortization of Deferred Charges | 193.22M | 193.22M | 193.22M | 193.22M | 245.84M |
| Total Other Non-Cash Items | 144.51M | 230.39M | 129.78M | 158.45M | 959.69M |
| Change in Net Operating Assets | -1.15B | 334.39M | -71.77M | -254.90M | 199.21M |
| Cash from Operations | 5.26B | 6.95B | 7.18B | 7.15B | 8.17B |
| Capital Expenditure | -1.19B | -1.10B | -1.05B | -1.05B | -1.08B |
| Sale of Property, Plant, and Equipment | 66.19M | 64.26M | 7.08M | 7.27M | 12.67M |
| Cash Acquisitions | -- | -- | -- | -- | 0.00 |
| Divestitures | 62.82M | 62.82M | 62.87M | 60.16M | 224.30M |
| Other Investing Activities | -5.13B | -5.03B | -4.80B | -3.60B | -636.00M |
| Cash from Investing | -6.19B | -6.01B | -5.78B | -4.57B | -1.48B |
| Total Debt Issued | 495.00B | 325.00B | 325.00B | 115.00B | 0.00 |
| Total Debt Repaid | -450.19B | -619.88B | -473.58B | -400.07B | -498.95B |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -2.33B | -2.33B | -2.33B | -26.93B | -51.92B |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -2.03B | -2.01B | -2.03B | -2.07B | -2.08B |
| Other Financing Activities | -56.80B | -63.56B | -119.02B | -117.73B | -115.84B |
| Cash from Financing | -2.11B | -4.53B | -3.93B | -5.18B | -7.22B |
| Foreign Exchange rate Adjustments | 112.52M | 65.68M | 112.10M | 178.12M | 345.07M |
| Miscellaneous Cash Flow Adjustments | 6.30K | -14.40K | -14.40K | 600.00 | 600.00 |
| Net Change in Cash | -2.92B | -3.52B | -2.43B | -2.42B | -193.29M |